Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/22/2007WO2006130532A3 Treatment of liver diseases in which iron plays a role in pathogenesis
11/22/2007WO2006130416A3 Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators
11/22/2007WO2006129158A3 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
11/22/2007WO2006124375A3 Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
11/22/2007WO2006121719A3 Soluble epoxide hydrolase inhibitors and methods of using same
11/22/2007WO2006119329A3 Compositions and methods for the treatment of neurodegenerative diseases
11/22/2007WO2006114676A8 A process for the preparation of rupatadine
11/22/2007WO2006108149A3 Substituted benzylamines as cyp2a inhibitors and uses thereof to treat nicotine dependence
11/22/2007WO2006107316A8 Improved formulations of fenofibrate containing menthol or peg/poloxamer
11/22/2007WO2006104915A3 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS
11/22/2007WO2006104594A3 Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors
11/22/2007WO2006100208A9 1-benzylindole-2-carboxamide derivatives
11/22/2007WO2006099268A3 Cgrp receptor antagonists
11/22/2007WO2006096194A3 Drinkable immediate release tablet made with direct compression of memantine or neramexane
11/22/2007WO2006093813A3 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
11/22/2007WO2006091394A3 Substituted imidazoquinolines and imidazonaphthyridines
11/22/2007WO2006089270A3 Methods of modifying insulin signaling using biliverdin reductase
11/22/2007WO2006083622A3 Control of enterohemorrhagic e. coli in farm animal drinking water
11/22/2007WO2006076726A9 Synthesis of sodium narcistatin and related compounds
11/22/2007WO2006074003A3 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
11/22/2007WO2006073602A3 Rnai modulation of the bcr-abl fusion gene and uses thereof
11/22/2007WO2006057886A8 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES
11/22/2007WO2005117543A3 N-sulfonylcarboximidamide apoptosis promoters
11/22/2007WO2005115479A3 Peptide conjugated, inosine-substituted antisense oligomer compound and method
11/22/2007WO2005091909A3 Methods to increase reverse cholesterol transport in the retinal pigment epithelium (rpe) and bruch’s membrane (bm)
11/22/2007WO2005084349A3 Compounds useful for the synthesis of (+)-discodermolide and methods therefor
11/22/2007WO2005046589A3 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
11/22/2007WO2002047726A3 Pharmaceutical composition containing an active with a hemolytic action and a surfactant
11/22/2007WO2000018212A8 Platelet-derived growth factor c, dna coding therefor, and uses thereof
11/22/2007US20070270617 Crystalline forms of combretastatin A4 phosphate mono-tromethamine and histidine salts; improved water solubility; rapidly regenerates combretastatin A-4 in vivo
11/22/2007US20070270588 Pyrrolopyrimidine Derivatives
11/22/2007US20070270587 Pyrimidoindolones and methods for using same
11/22/2007US20070270505 Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto
11/22/2007US20070270503 Penetration of Active Substances Into Cells and Organs
11/22/2007US20070270501 Medicaments for Treating Barrett's Eesophagus
11/22/2007US20070270500 Compositions Comprising Cyclohexylamines and Aminoadamantanes
11/22/2007US20070270499 Use for 2-amino-2-propane-1, 3-diols
11/22/2007US20070270498 Therapeutic fluoroethyl ureas
11/22/2007US20070270497 Agent For Recovery From Cerebral Fatigue
11/22/2007US20070270496 Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
11/22/2007US20070270495 Use of Cystine or Cysteine for the Prevention and Treatment of Oxidative Stress Cause by Haemodialysis and of Acute or Chronic Kidney Diseases
11/22/2007US20070270494 nucleic acid sequence encoding an acyl-CoA synthetase (ACoAS) that catalyzes the conversion of long chain PUFA free fatty acids (FFA) to acyl-CoA; transforming an organism to express PUFAs; improved methods of production of PUFAs
11/22/2007US20070270493 Composition with Preventive or Improvement Effect on Stress-Induced Brain Function Impairment and Related Symptoms or Diseases
11/22/2007US20070270492 Nananoic acid derivatives as dipeptidyl peptidase inhibitors
11/22/2007US20070270491 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
11/22/2007US20070270490 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
11/22/2007US20070270489 Remedy for Cartilage-Related Diseases
11/22/2007US20070270488 Treatment and Assays
11/22/2007US20070270487 Novel process and intermediates 085
11/22/2007US20070270486 Compositions and methods for high throughput screening of pharmacological chaperones
11/22/2007US20070270485 Byrostatin analogues, synthetic methods and uses
11/22/2007US20070270484 3'-N-Substituted-3-O-Substituted Erythronolide a Derivatives
11/22/2007US20070270483 Process for the preparation of aryloxypropylamines
11/22/2007US20070270482 Cytotoxic Agents Comprising New C-2 Modified Taxanes
11/22/2007US20070270481 Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
11/22/2007US20070270480 Biphenyl Derived Thiamides as Calpain Inhibitors
11/22/2007US20070270479 New pyrazole derivatives and diabetic medicine containing them
11/22/2007US20070270478 e.g. 3-[4-(3,5-bis-trifluoromethyl-pyrazol-1-yl)-phenyl]-2-(2,3-difluoro-phenyl)-acrylonitrile; immunosuppressant; bioavailability; side effect reduction; interleukin-2 inhibitor
11/22/2007US20070270477 Agent for Prophylaxis or Treatment of Metabolic Syndrome
11/22/2007US20070270476 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
11/22/2007US20070270474 Pyrazole compounds for treatment of neurodegenerative disorders
11/22/2007US20070270473 Sulfonamide Compounds and Uses Thereof
11/22/2007US20070270472 Amino, Amino Acid or Peptide Conjugates of Retinoic Acid
11/22/2007US20070270471 Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine
11/22/2007US20070270470 N-[[4-(4-bromophenyl)-5-(2,4-dichlorophenyl)-3-methyl-2-thienyl]methyl]-2-ethylbutanamide; cannabinoid CB1 receptor antagonists
11/22/2007US20070270469 e.g. 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine hydrochloride; glutamate mGluR5 receptor modulator; antidepressant, anxiolytic, analgesic agent; neurodegenerative disorder
11/22/2007US20070270468 e.g. 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine hydrochloride; glutamate mGluR5 receptor modulator; antidepressant, anxiolytic, analgesic agent; neurodegenerative disorder
11/22/2007US20070270467 Substituted piperidines as modulators of dopamine neurotransmission
11/22/2007US20070270466 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists
11/22/2007US20070270465 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl) piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
11/22/2007US20070270464 Prodrugs of curcumin analogs
11/22/2007US20070270463 such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-6-ylmethylsulfonamide; azeotropic distillation, crystallization; central nervous system disorders
11/22/2007US20070270462 8-hydroxyquinoline compounds for treating a polyglutamine (polyQ)-expansion disease
11/22/2007US20070270460 Substituted tetrahydroisoquinoline compounds, methods of making, and their use
11/22/2007US20070270459 Overactive bladder treating drug
11/22/2007US20070270458 Nicotinic Acetylcholine Receptor Ligands
11/22/2007US20070270457 Quinolinone-carboxamide compounds as 5-HT, receptor agonists
11/22/2007US20070270456 M3 Muscarinic Acetylcholine Receptor Antagonists
11/22/2007US20070270455 INHIBITION OF NF-kB
11/22/2007US20070270454 Huperzine a compound for treatment of Alzheimer's disease
11/22/2007US20070270453 TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
11/22/2007US20070270452 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
11/22/2007US20070270451 Methods of preparing pimecrolimus
11/22/2007US20070270450 Compositions for affecting weight loss
11/22/2007US20070270449 5 ht receptor mediated neurogenesis
11/22/2007US20070270448 Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders
11/22/2007US20070270447 Consists of polyurethane and 5-fluorouracil; inhibits or reduces incidence of infection
11/22/2007US20070270446 Reversed Pyrimidinone Compounds as Calcilytics
11/22/2007US20070270445 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
11/22/2007US20070270444 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3
11/22/2007US20070270443 Methods and compositions for the treatment of viral infections
11/22/2007US20070270442 Combination of a Cdk Inhibitor and Cs-682 or a Metabolite Thereof
11/22/2007US20070270441 Combination
11/22/2007US20070270440 (3'S)-1'-(4-phenoxybenzoyl)-1,3'-bipyrrolidine, used for treating nervous system disorders, such as Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, obesity and sleep disorders
11/22/2007US20070270439 nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents
11/22/2007US20070270438 Cycloalkylamino acid derivatives
11/22/2007US20070270437 Such as 5-{6-[(Methylsulfonyl)methyl]-1H-benzimidazol-1-yl}-3-({(1R)-1-[2-(trifluoromethyl)phenyl]-ethyl}oxy)-2-thiophenecarboxamide; for conditions associated with polo-like kinases
11/22/2007US20070270436 Novel amino- and imino-alkylpiperazines
11/22/2007US20070270435 Novel Compounds
11/22/2007US20070270434 4-(4-(3-Fluoro-4-(trifluoromethyl)benzyl)-cis-2,6-dimethylpiperazin-1-ylsulfonyl)-2,3-dihydro-1H-indene-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia
1 ... 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 ... 7860